Our Company
- Premark Pharma is a privately-owned company, established in Switzerland in April 2018
- The lead investor is a consortium of US-based ophthalmologists
- The team includes experts in ophthalmic clinical practice, drug development and strategic marketing
Our Target
- Blepharitis is a common, chronic inflammatory eye disease for which there is currently no approved treatment
- Premark Pharma’s primary business objective is to achieve a marketing approval in EU and US for the first prescription treatment for blepharitis
Our Lead Asset
- PMP2207 is a novel ocular anti-inflammatory
- In a robustly designed Phase II study, when compared to vehicle, PMP2207 demonstrated a more rapid and sustained improvement in both the signs and symptoms of blepharitis
- PMP2207 will be advanced into a Phase III programme in the coming months